Sugi Predict

Sugi Predict / Compounds / SCHEMBL3584346

SCHEMBL3584346

SCHEMBL3584346

Cc1cc(Nc2cc(C(N)=O)ccc2C)n(-c2cc(Nc3ccc(CN4CCOCC4)cn3)ncn2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.42
▸ RPS6KB1 P23443 1/20 0.42
▸ CHUK O15111 2/20 0.41
▸ MAPK8 P45983 2/20 0.41
▸ CAMKK2 Q96RR4 2/20 0.41
▸ INSR P06213 2/20 0.40
▸ ADORA2A P29274 3/20 0.40
▸ KDR P35968 2/20 0.40
▸ LCK P06239 2/20 0.40
▸ LYN P07948 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ F10 P00742 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ EPAS1 Q99814 1/20 0.38
▸ ADORA1 P30542 2/20 0.38
▸ BRAF P15056 2/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ MAPK14 Q16539 4/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584350 0.88 LCK (0.41) AURKARPS6KB1INSRADORA2AKDR
SCHEMBL3596858 0.84 MAPK14 (0.45) BRAFMAPK14
SCHEMBL3588778 0.84 MAPK14 (0.41) AURKARPS6KB1INSRADORA2AKDR
SCHEMBL3579677 0.84 CYP1A2 (0.47) INSRKDRLCKLYNSRC
SCHEMBL9970945 0.83 FLT3 (0.42) ADORA2ABRAFMAPK14IKBKETBK1
SCHEMBL3590161 0.81 BRAF (0.43) CHUKMAPK8CAMKK2INSRBRAF
SCHEMBL3587592 0.81 BRAF (0.46) INSRKDRLCKLYNSRC
SCHEMBL9967438 0.81 FLT3 (0.44) HIF1AEPAS1BRAFMAPK14CDK2
SCHEMBL3594677 0.78 MAPT (0.47) LCKBRAFMAPK14
SCHEMBL3587792 0.72 CSF1R (0.51) INSRKDRLCKLYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 — — US claimed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 — — US claimed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 — — EP claimed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 — — WO claimed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 — — US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 — — US disclosed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 — — EP disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK AURKA 261/4885RPS6KB1 499/4885CHUK 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.